You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 20, 2024

CLINICAL TRIALS PROFILE FOR APROCITENTAN

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for APROCITENTAN

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02603809 ↗	Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension	Completed	Actelion	Phase 2	2015-12-14	The main objective will be to evaluate the dose-response of ACT-132577 (aprocitentan) on diastolic blood pressure (DBP) in participants with grade 1 or 2 essential hypertension. Secondary objectives will be to evaluate the dose-response of ACT-132577 on: systolic blood pressure (SBP); control and response rate of blood pressure; 24-hour ambulatory blood pressure monitoring (ABPM) and to evaluate the safety and tolerability of a once daily oral regimen of 4 doses of ACT-132577.
NCT02603809 ↗	Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension	Completed	Idorsia Pharmaceuticals Ltd.	Phase 2	2015-12-14	The main objective will be to evaluate the dose-response of ACT-132577 (aprocitentan) on diastolic blood pressure (DBP) in participants with grade 1 or 2 essential hypertension. Secondary objectives will be to evaluate the dose-response of ACT-132577 on: systolic blood pressure (SBP); control and response rate of blood pressure; 24-hour ambulatory blood pressure monitoring (ABPM) and to evaluate the safety and tolerability of a once daily oral regimen of 4 doses of ACT-132577.
NCT03541174 ↗	A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety	Active, not recruiting	Janssen Biotech, Inc.	Phase 3	2018-06-18	The purpose of the study is to show the blood pressure lowering effect of aprocitentan, a new drug, when added to other anti-hypertensive drugs of patients with difficult to control (resistant) high blood pressure (hypertension), and to show that blood pressure reduction is kept for long period of time.
NCT03541174 ↗	A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety	Active, not recruiting	Idorsia Pharmaceuticals Ltd.	Phase 3	2018-06-18	The purpose of the study is to show the blood pressure lowering effect of aprocitentan, a new drug, when added to other anti-hypertensive drugs of patients with difficult to control (resistant) high blood pressure (hypertension), and to show that blood pressure reduction is kept for long period of time.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for APROCITENTAN

Condition Name

Chart
Table

Condition Name for APROCITENTAN
Intervention	Trials
Healthy Subjects	4
Arterial Hypertension, Pulmonary	1
Essential Hypertension	1
Hepatic Impairment	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for APROCITENTAN
Intervention	Trials
Hypertension	3
Renal Insufficiency	1
Kidney Diseases	1
Pulmonary Arterial Hypertension	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for APROCITENTAN

Trials by Country

Map
Table

Trials by Country for APROCITENTAN
Location	Trials
United States	54
Australia	5
Canada	5
Korea, Republic of	4
Germany	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for APROCITENTAN
Location	Trials
California	3
Pennsylvania	2
Oregon	2
Ohio	2
North Carolina	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for APROCITENTAN

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for APROCITENTAN
Clinical Trial Phase	Trials
Phase 3	2
Phase 2	1
Phase 1	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for APROCITENTAN
Clinical Trial Phase	Trials
Completed	4
Recruiting	2
Withdrawn	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for APROCITENTAN

Sponsor Name

Chart
Table

Sponsor Name for APROCITENTAN
Sponsor	Trials
Idorsia Pharmaceuticals Ltd.	7
Janssen Biotech, Inc.	3
Actelion	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for APROCITENTAN
Sponsor	Trials
Industry	12
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.